---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-013092"
form_type: "8-K"
ticker: null
cik: "0001445499"
company_name: "IMPEL PHARMACEUTICALS INC"
filed_at: "2023-04-17T23:59:59+00:00"
generated_at: "2026-06-17T01:19:10.428336+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Impel Pharmaceuticals receives Nasdaq delisting notifications for failing market value requirements

## Summary
- On April 11, 2023, Impel received Nasdaq notices for non-compliance with MVPHS ($15M minimum) and MVLS ($50M minimum) rules.
- Company has 180 calendar days (until October 9, 2023) to regain compliance by closing above thresholds for 10 consecutive business days.
- If unable to comply, Impel may request a hearing to appeal a potential delisting determination.
- Management will monitor market values and consider options to regain compliance, but no assurance of success.
- Common stock trades on Nasdaq under ticker IMPL; failure to comply could lead to delisting.

## SEC filing metadata
- accession: 0000950170-23-013092
- form_type: 8-K
- cik: 0001445499
- company_name: IMPEL PHARMACEUTICALS INC
- filed_at: 2023-04-17T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445499/000095017023013092/0000950170-23-013092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445499/000095017023013092/impl-20230411.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-013092
- JSON: https://secwatch.observer/filing/0000950170-23-013092.json
- Plain text: https://secwatch.observer/filing/0000950170-23-013092.txt

## Key facts
- Listing & Compliance Notices
  IMPEL PHARMACEUTICALS INC received a nasdaq noncompliance notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C)).
  - Exchange: nasdaq
  - Notice: noncompliance notice
  - Deficiency: market value
  - Rules: 5450(b)(2)(A), 5450(b)(2)(C)
  source text: April 11, 2023, Impel Pharmaceuticals Inc. (the “Company”) received two written notifications from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”). The first notification indicated that as of April 11, 2023, the Company did not meet the $15,000,000 minimum market value of publicly held shares required to maintain continued listing as set forth in Nasdaq Marketplace Rule 5450(b)(2)(C) (the “MVPHS Rule”) for the 30-business day period ended April 5, 2023. The second notification indicated that as of April 11, 2023, the Company did not meet the $50,000,000 minimum
  evidence_url: https://www.sec.gov/Archives/edgar/data/1445499/000095017023013092/0000950170-23-013092-index.htm
- Listing & Compliance Notices
  IMPEL PHARMACEUTICALS INC received a nasdaq noncompliance notice notice regarding market value (rules 5450(b)(2)(C)).
  - Exchange: nasdaq
  - Notice: noncompliance notice
  - Deficiency: market value
  - Rules: 5450(b)(2)(C)
  source text: April 11, 2023, Impel Pharmaceuticals Inc. (the “Company”) received two written notifications from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”). The first notification indicated that as of April 11, 2023, the Company did not meet the $15,000,000 minimum market value of publicly held shares required to maintain continued listing as set forth in Nasdaq Marketplace Rule 5450(b)(2)(C) (the “MVPHS Rule”) for the 30-business day period ended April 5, 2023. The second notification indicated that as of April 11, 2023, the Company did not meet the $50,000,000 minimum
  evidence_url: https://www.sec.gov/Archives/edgar/data/1445499/000095017023013092/0000950170-23-013092-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.